• Something wrong with this record ?

Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry

A. Colombo, J. Chandrasekhar, M. Aquino, TK. Ong, S. Sartori, U. Baber, M. Lee, A. Iniguez, P. Hajek, B. Borisov, B. Atzev, P. Den Heijer, Z. Coufal, M. Hudec, M. Mates, C. Snyder, K. Moalem, D. Morrell, F. Elmore, S. Rowland, R. Mehran, MASCOT...

. 2019 ; 283 (-) : 67-72. [pub] 20190121

Language English Country Netherlands

Document type Journal Article, Multicenter Study, Observational Study

Persistent link   https://www.medvik.cz/link/bmc19044958

BACKGROUND: The COMBO stent (OrbusNeich Medical, Ft. Lauderdale, Florida) is a new-generation bio-engineered drug eluting stent, combining an abluminal coating of a bioabsorbable polymer matrix for sustained release of sirolimus and luminal anti-CD34 coating for endothelial progenitor cell capture and rapid endothelialization. METHODS: The Multinational Abluminal Sirolimus Coated BiO-Engineered StenT (MASCOT) registry was a prospective post-marketing study conducted from June 2014-May 2017 across 60 centers globally. Patients were eligible if COMBO stent implantation was attempted, and they received dual antiplatelet therapy (DAPT) per local guidelines. Follow-up was conducted by trained research staff at 1, 6 and 12 months by phone or clinic visit to capture clinical events and DAPT cessation events. The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, non-fatal myocardial infarction not clearly attributable to a non-target vessel, or ischemia-driven target lesion revascularization. RESULTS: A total of 2614 patients were enrolled over the study period with 96.7% completion of 1-year follow-up. The mean age of enrolled patients was 62.9 ± 11.2 years and 23.0% were female. Diabetes mellitus was present at baseline in 33.5%. A total of 56.1% patients underwent PCI for acute coronary syndrome (ACS). The 1-year primary endpoint of TLF occurred in 3.4% patients (n = 88). Definite stent thrombosis occurred in 0.5% patients (n = 12). CONCLUSION: The MASCOT post marketing registry provides comprehensive safety and efficacy outcomes following contemporary PCI using the novel COMBO stent in an all-comer population. This platform is associated with low rates of 1-year TLF and ST. CLINICALTRIALS. GOV IDENTIFIER: NCT02183454.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044958
003      
CZ-PrNML
005      
20200114145218.0
007      
ta
008      
200109s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcard.2019.01.053 $2 doi
035    __
$a (PubMed)30826192
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Colombo, Antonio $u San Raffaele Scientific Institute, Milan, Italy.
245    10
$a Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry / $c A. Colombo, J. Chandrasekhar, M. Aquino, TK. Ong, S. Sartori, U. Baber, M. Lee, A. Iniguez, P. Hajek, B. Borisov, B. Atzev, P. Den Heijer, Z. Coufal, M. Hudec, M. Mates, C. Snyder, K. Moalem, D. Morrell, F. Elmore, S. Rowland, R. Mehran, MASCOT Investigators,
520    9_
$a BACKGROUND: The COMBO stent (OrbusNeich Medical, Ft. Lauderdale, Florida) is a new-generation bio-engineered drug eluting stent, combining an abluminal coating of a bioabsorbable polymer matrix for sustained release of sirolimus and luminal anti-CD34 coating for endothelial progenitor cell capture and rapid endothelialization. METHODS: The Multinational Abluminal Sirolimus Coated BiO-Engineered StenT (MASCOT) registry was a prospective post-marketing study conducted from June 2014-May 2017 across 60 centers globally. Patients were eligible if COMBO stent implantation was attempted, and they received dual antiplatelet therapy (DAPT) per local guidelines. Follow-up was conducted by trained research staff at 1, 6 and 12 months by phone or clinic visit to capture clinical events and DAPT cessation events. The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, non-fatal myocardial infarction not clearly attributable to a non-target vessel, or ischemia-driven target lesion revascularization. RESULTS: A total of 2614 patients were enrolled over the study period with 96.7% completion of 1-year follow-up. The mean age of enrolled patients was 62.9 ± 11.2 years and 23.0% were female. Diabetes mellitus was present at baseline in 33.5%. A total of 56.1% patients underwent PCI for acute coronary syndrome (ACS). The 1-year primary endpoint of TLF occurred in 3.4% patients (n = 88). Definite stent thrombosis occurred in 0.5% patients (n = 12). CONCLUSION: The MASCOT post marketing registry provides comprehensive safety and efficacy outcomes following contemporary PCI using the novel COMBO stent in an all-comer population. This platform is associated with low rates of 1-year TLF and ST. CLINICALTRIALS. GOV IDENTIFIER: NCT02183454.
650    _2
$a bioinženýrství $x metody $7 D057005
650    _2
$a nemoci koronárních tepen $x chirurgie $7 D003324
650    12
$a stenty uvolňující léky $7 D054855
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x farmakologie $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a koronární angioplastika $x metody $7 D062645
650    _2
$a postmarketingový dozor $x statistika a číselné údaje $7 D011358
650    _2
$a protézy - design $7 D011474
650    12
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sirolimus $x farmakologie $7 D020123
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Chandrasekhar, Jaya $u Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Aquino, Melissa $u Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Ong, Tiong Kiam $u Pusat Jantung Hospital Umum Sarawak, Sarawak, Malaysia.
700    1_
$a Sartori, Samantha $u Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Baber, Usman $u Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Lee, Michael $u Queen Elizabeth Hospital, Singapore.
700    1_
$a Iniguez, Andres $u Meixoeiro Hospital - University Hospital of Vigo, Vigo, Spain.
700    1_
$a Hajek, Petr $u 2nd Faculty of Medicine and Motol University Hospital, Praha, Czech Republic.
700    1_
$a Borisov, Borislav $u MBAL St. Ivan Rilski, Stara Zagora, Bulgaria.
700    1_
$a Atzev, Borislav $u MBAL Puls, Blagoevgrad, Blagoevgrad, Bulgaria.
700    1_
$a Den Heijer, Peter $u Amphia Hospital - Breda, Breda, Netherlands.
700    1_
$a Coufal, Zdenek $u T. Bata Regional Hospital Zlin, Zlin, Czech Republic.
700    1_
$a Hudec, Martin $u SuSCH Banská Bystrica, Banská Bystrica, Slovakia.
700    1_
$a Mates, Martin $u Nemocnice na Homolce, Praha 5, Czech Republic.
700    1_
$a Snyder, Clayton $u Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Moalem, Kamilia $u Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Morrell, Deborah $u OrbusNeich Ltd, Fort Lauderdale, FL, USA.
700    1_
$a Elmore, Francesca $u OrbusNeich Ltd, Fort Lauderdale, FL, USA.
700    1_
$a Rowland, Stephen $u OrbusNeich Ltd, Fort Lauderdale, FL, USA.
700    1_
$a Mehran, Roxana $u Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: Roxana.mehran@mountsinai.org.
710    2_
$a MASCOT Investigators
773    0_
$w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 283, č. - (2019), s. 67-72
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30826192 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200114145551 $b ABA008
999    __
$a ok $b bmc $g 1483227 $s 1083631
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 283 $c - $d 67-72 $e 20190121 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options